Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of pegylated interferon lambda with ribavirin and direct-acting antivirals versus Pegasys plus ribavirin in treatment-naive genotype 1 chronic hepatitis C
2010-022568-11Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of peginterferon lambda-1a, daclatasvir, asunaprevir, ribavirin and interferon alfa in hepatitis C virus infection (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability through end of treatment plus 30 days. Started Jan 2011; status: completed.
02
Drugs
peginterferon lambda-1adaclatasvirasunaprevirribavirininterferon alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-022568-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022568-11.